NCT03683433 2026-03-05Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene MutationM.D. Anderson Cancer CenterPhase 2 Recruiting50 enrolled